Compare FRD & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRD | ELDN |
|---|---|---|
| Founded | 1965 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.2M | 291.8M |
| IPO Year | 1995 | 2014 |
| Metric | FRD | ELDN |
|---|---|---|
| Price | $39.26 | $2.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 47.1K | ★ 899.1K |
| Earning Date | 06-11-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | N/A | ★ 30.67 |
| EPS | ★ 1.79 | N/A |
| Revenue | ★ $121,157,278.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.02 | ★ N/A |
| Revenue Growth | ★ 55.82 | N/A |
| 52 Week Low | $16.55 | $1.35 |
| 52 Week High | $48.77 | $4.60 |
| Indicator | FRD | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 39.66 | 29.58 |
| Support Level | $30.68 | $1.96 |
| Resistance Level | $39.07 | $3.18 |
| Average True Range (ATR) | 1.66 | 0.16 |
| MACD | -0.50 | 0.01 |
| Stochastic Oscillator | 7.25 | 0.88 |
Friedman Industries Inc is a manufacturer and processor of metals and operates in two reportable segments: flat-roll products and tubular products. The flat-roll product segment consists of flat-roll processing facilities located in Hickman, Arkansas; Decatur, Alabama; Miami, Florida; East Chicago, Indiana; Granite City, Illinois and Sinton, Texas and a flat-roll distribution facility located in Orlando, Florida. The tubular product segment consists of the Company's Texas Tubular Products division (TTP) located in Lone Star, Texas. TTP operates two electric resistance welded pipe mills with a combined outside diameter (OD). Its products are flat-roll products and tubular products.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.